Introduction
============

Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy, 238,700 new cancer cases and 151,900 cancer deaths worldwide were recorded in the 2012 [@B1]. EOC represents the eighth cause of death for tumor in the women worldwide [@B1]. In the 2016, the Italian Association of Cancer Registries reported 5,200 new cancer cases and 3,302 cancer deaths [@B2]. Five years overall survival (OS) is of 45% [@B3] because EOC is usually diagnosed at advanced stage and no specific symptoms or diagnostic tools are available for early diagnosis [@B3],[@B4]. When EOC is limited to the ovary (stages IA and IB), 5 years OS raise to 92%. However, only 15% of all EOC are found at this early stage [@B3] therefore EOC diagnosis is usually characterized by severe physical and psychological sequelae [@B5]. Border line ovarian tumors (BOT) are less aggressive of EOC and affect women younger than those affected by EOC. Usually, BOT require only a surgical therapy and are characterized by a good prognosis.

Well know prognostic factors are age, obesity, performance status, histology, stage, grade, centralization and residual disease after surgery [@B6], [@B7].

Several new prognostic factors in EOC have been investigated such as tumor suppressor protein 53 (p53), oncogenes epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER-2/neu), B-cell lymphoma 2 (Bcl-2), haptoglobin, but results of a recent meta-analysis showed that these biomarkers do not have a strong direct relationship with survival, although likely their respective pathways do influence patients prognosis [@B6], [@B8], [@B9].

Since the first link between AB0 blood type and cancer was described in 1953, numerous studies investigated the association between AB0 blood group with gynecological [@B10] and non-gynecological cancers [@B11], [@B12].

Recently, meta-analysis confirmed that non-0 blood types are associated with significantly increased risk of gastric and pancreatic cancer [@B12]-[@B15], on contrary, for the other malignancies, data are inconsistent [@B13].

Since fifties, also the interaction between AB0 blood group and EOC has been investigated by several studies [@B16]-[@B31] but frequently conflicting results have been published (Table [1](#T1){ref-type="table"}).

Here, we investigated the association between AB0 blood group with both BOT and EOC in the patients consecutively surgically treated at our department from 2004 to 2015.

Materials and Methods
=====================

Patient characteristics
-----------------------

The study was designed following the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement [@B32]. The Local Ethical Committee approved the study design and all patients provided written informed consent to use personal non-sensitive data at hospital admission.

Clinical charts of BOT and invasive epithelial ovarian cancer (EOC) patients treated and followed at the IRCCS - Santa Maria Nuova Hospital of Reggio Emilia (Italy) from 2004 to 2015 were checked for inclusion and exclusion criteria.

Clinical and pathological data were recorded in an electronic separate, anonymous, password- protected database. All relevant data were extrapolated and used for final analysis.

Patients with histological diagnosis of BOT and EOC who received adequate treatment were electively included in the protocol study. Exclusion criteria were: histological diagnosis of benign ovarian tumor, inadequate EOC management according to internal and international guidelines [@B33]-[@B35], an age less than 18 years, non-Caucasian ancestry, a follow-up length less than of 6 months, inadequate follow-up according to internal guidelines, absence of written informed consent, diagnosis of a previous or concurrent cancer(s) and unavailable follow-up data**.**

An "adequate" management was considered as follows: in apparent early stage BOT a total extrafascial hysterectomy (TEH) with bilateral salpingo- oophorectomy (BSO) infracolonic omentectomy, multiple peritoneal biopsy and peritoneal washing was the standard staging procedure; appendectomy was performed in case of mucinous histotype; whereas additional procedures such as radical omentectomy, pelvic and paraaortic lymph node dissection were performed in case of early stage EOC. In case of BOT with multiple implants or advanced EOC a debulking surgery with excision of all macroscopic disease was performed. In these cases additional procedures such as bowel resection, spelenectomy, liver resection, diaframmectomy, peritonectomy were performed. Adjuvant chemotherapy should be administered to early stage suboptimally staged patients and to those at early stage optimally staged patients at higher risk of recurrence such as stage 1B/C grade 2/3, any grade 3 or clear-cell histology [@B33]-[@B35]. Moreover, chemotherapy is recommended for all patients with FIGO stage II-IV disease post-surgery. Standard chemotherapy consists of a combination of paclitaxel 175 mg/m2 and carboplatin AUC 6-5, both administered intravenously every three weeks for six months [@B34],[@B35]. Since 2013 anti-angiogenic therapy was added to the standard therapy for FIGO stage IIIb-IV. Bevacizumab was offered at 7.5 mg/kg IV repeated every three weeks for six cycles and continued for up to 12 additional cycles [@B34],[@B35]. Women affected by severe comorbidity or unresectable disease at upfront surgery were submitted to neoadjuvant chemotherapy. Neoadjuvant chemotherapy consisted of 3/4 cycles of combination of paclitaxel and carboplatin. A follow- up was defined "adequate" in case of adherence to the following schedule: physical and gynecological examination, and transvaginal ultrasound every 12 months, CA 125 evaluation and chest/abdominal/ pelvic computed tomography scan every 6 months for 5 years.

Further investigations such as chest X-ray, positron emission tomography scan were performed if clinically indicated.

The same pathologists with long-time expertise in gynecological oncology reviewed all the histological samples in order to confirm formally the diagnosis.

Statistical analysis
--------------------

For statistical analysis R statistical software package version 3.1.1 (R foundation for Statistical Computing, Vienna, Austria) was used.

Univariate associations between AB0 genotypes and clinic-pathological variables were assessed by Fisher\'s exact test and generalized linear models.

The overall survival (OS) was calculated as the period spent from the date of surgery to the date of death or last follow up. Analyses of overall survival between AB0 blood groups were performed applying Cox regression hazard model and Hazard ratio (HR) values were calculated. Kaplan Meier curves were used to represent overall survival trends in different groups of patients.

Significant statements referred P values lower than 0.05.

Results
=======

Patient characteristics
-----------------------

A population of 265 patients with BOT and EOC selected for inclusion and exclusion criteria was analyzed in this study. One hundred and twenty one (45.6%) patients presented blood type 0, 112 (42.3%) had blood type A, 23 (8.7%) B and 9 (3.4%) AB. Blood groups frequencies overlapped with those described for total Italian population (0: 46%, A: 42%, B: 9%, AB: 3%).

In table [2](#T2){ref-type="table"} the distribution of AB0 groups was investigate in association with principal clinical and pathological characteristics of patients. Interestingly we observed a significantly lower percentage of death (8.7%) (p= 0.024) in patients with blood type B in comparison with patients presenting different genotypes (group 0: 34.7%, group A: 32.1%, group AB: 22.2%).

AB0 blood groups and invasive ovarian cancer
--------------------------------------------

To better investigate the relation between B group and risk of death in ovarian cancer patients we excluded BOT and performed an OS analysis focusing on 224 EOC and subsequently on a subgroup of 176 more aggressive serous invasive tumors because no significant correlation was found with histotypes other than serous (data not shown). In all EOC and particularly in serous EOC the analysis confirmed the protective role of B genotype in EOC risk, showing about a 5 fold significant reduction of the risk of death (Table [3](#T3){ref-type="table"}, Fig. [1](#F1){ref-type="fig"}).

Further analyses were focused on the serous invasive tumors and a univariate and multivariate survival analysis including the principal clinical and pathological characteristics of these patients were included. (Table [4](#T4){ref-type="table"}). As expected, in univariate analysis, in addition to blood group, age, neoadjuvant therapy and presence of residual tumor after surgery resulted the principal parameters influencing OS of serous EOC patients.

A bootstrap approach (b=1000) was used to perform an internal validation of the univariate association between AB0 group and OS. Analysis conducted on total population (p=0.022), EOC (p= 0.049) and serous invasive EOC (0.084) confirmed the significant effect of blood groups on the risk of death.

Because the evident effect of the presence of residual tumor (RT) on patients survival two different model of multivariate analysis were considered. In model 1 postoperative RT and neoadjuvant therapy were excluded from the analysis and a significant, independent effect of blood group B (Hazard ratio (HR)=0.20, P adjusted=0.041) and age (HR=1.04, P adjusted=0.015) on the risk of death in serous EOC was confirmed. In model 2 of multivariate analysis the presence of postoperative RT resulted the most important prognostic factor for OS (HR=3.54, P adjusted= 0.004) and both blood group and neoadjuvant therapy loss their significant effect.

Discussion
==========

In this retrospective study, B blood type patients showed a better OS compared with non-B blood- type patients both in BOT and EOC patients (Fig.[1](#F1){ref-type="fig"}a). This result was confirmed also in the group of only EOC patients (Fig.[1](#F1){ref-type="fig"}b) and in the group of only serous EOC patients (Fig. [1](#F1){ref-type="fig"}c).

To date, 16 studies investigated the impact of AB0 blood-group on EOC with different results (Table [1](#T1){ref-type="table"}) [@B16]-[@B31]. Most of these studies reported that A blood type was associated with an increased ovarian cancer risk, particularly in premenopausal women [@B22]. Moreover, A blood type was associated with worse OS [@B19], [@B23], especially in patients over 50 years of age [@B19]. A recent meta-analysis including 9956 EOC patients coming from 7 studies, confirmed that A blood type was associated with increased EOC risk, on contrary 0 blood type was associated with decreased EOC risk [@B19], [@B25]. Poole in a genotyping study on 5232 EOC patients showed a modestly increased EOC risk particularly in A0 but not AA diplotype [@B17]. Differently by previous studies, Gates reported that B antigen was positively associated with an increased incidence of EOC and A antigen was not [@B21]. Moreover, in a Chinese cohort study, B blood group was associated with a reduced risk of genitourinary cancer in male [@B36].

How AB0 antigens may influence EOC prognosis is not well established. AB0 antigens are expressed on many cell types including platelets, vascular endothelial cells, epithelial tissues, mucus secretions [@B12] and tumor cells. Moreover, A antigen can be detected also in tumor cells from non-A individuals. A dysregulation of the enzymatic activity of the AB0 glycosyltransferases, can lead to conformational changes in proteins, such as the epidermal growth factor receptor or alter immune recognition of natural killer cells which are specifically involved in the processes of intercellular adhesion and cellular membrane signaling as well as in the immune response to the host [@B37]-[@B39]. These are all conditions that favor tumorigenesis [@B40].

Recently, studies reported an association between polymorphisms at the AB0 gene locus and circulating levels of tumour necrosis factor-alpha, soluble intercellular adhesion molecule (ICAM)-1 [@B41]. ICAM-1 is used by cancer cells for adhesion to endothelial cells and subsequent metastatisation [@B42], the decreased soluble ICAM levels in patients with A blood group may promote metastatic spread of tumours [@B15].

The AB0 gene is located on chromosome 9q34 encodes glycosyltransferases, which is frequently lost in EOC [@B43], [@B44]. The gene encodes for glycosyltransferases, which catalyze the step-by-step transfer of nucleotide donor sugars to the H antigen to form the A and B antigen [@B44]. Aberrant glycosylation represents a hallmark of cancer development and progression [@B45]. Thus, some authors hypothesized that patients with blood type A have impacted tumor cell invasion and immune responses of EOC cells and more susceptible to disease failure [@B18].

Moreover, AB0 blood group antigen expression on cancer cells is modified by hypermethylation of AB0 gene promoter [@B46], which might be related with the tumor invasion and metastasis. The number of methylated gene promoters increased with age [@B47], [@B48], which may partly explain the reason for patients with age \> 50 years had worse OS [@B18].

Age is a well know prognostic factor in EOC patients, in our study at univariate analysis age, AB0 blood group, FIGO stage, neoadjuvant therapy, invasiveness and postoperative RT resulted to affect OS, but at multivariate analysis only age, FIGO stage and postoperative RT resulted to affect OS whilst AB0 blood group continued to affect OS only if postoperative RT was not included in multivariate analysis. So we may hypothesize that AB0 blood group might be a preoperative prognostic factor of EOC patients. According to the literature, postoperative residual disease remains the most important prognostic factor also in our study (HR 2.82).

In a previous study [@B18] on 256 EOC patients, blood group antigen A was associated with a significantly worse OS at multivariate analysis, but only patients without RT were analyzed.

Our findings confirm data coming from a recent multi-centre study [@B31] in which blood group antigen B was associated with a prolonged survival in patients with serous or undifferentiated EOC but this effect was not independent from standard prognostic parameters in multivariate analysis [@B31]. Differently from the latest studies [@B18],[@B31], we investigated also BOT in the total population (Fig.[1](#F1){ref-type="fig"}a).

Most previous studies have potential flaws [@B17], relied on self-reported blood group [@B18], showed a tendency to over-report the less common blood groups [@B15], had lack of adjustment for potential confounders, such as age and race and postoperative RT [@B18], [@B21].

In our study we included only patients with blood group assessed at our hospital, AB0 frequencies were comparable to the common population, oncologic outcome were similar to that reported in literature, we tested the impact of AB0 blood group for all well know prognostic factors such as age and postoperative residual tumor. A single-centre study guarantees uniformity in surgical/medical treatment, pathological evaluation and management of patients. On contrary, the main limitation of the present study is the small sample size.

Considering the wide distribution of AB0 antigens on several cells and secretion and the several cellular functions based on AB0 antigens, it is unlike to exclude a function of AB0 in cancer risk and development. Despite several plausible mechanisms are reported to justify the link between AB0 and cancer, only gastric and pancreatic cancer showed a clear link [@B12], [@B15], on contrary EOC is still under investigation. A blood group is the most reported to be associated with EOC risk and poor OS, B blood group seems to be associated with a better OS in our study. AB0 blood group is present in all population, is easy and cheap to test and might represent a useful prognostic factor to use in the preoperative evaluation. Largest cooperative study should be planned to obtain a likely answer.

Author Contributions
====================

All authors have made substantial contributions to the conception and design of the study. V.D.M. performed operations, conceived and designed the study and wrote the manuscript. F.T. performed statistical analysis, analyzed the data and wrote the manuscript. V.M. recruited patients, collected data and revised the literature. G.C. D.P., G.A., M.A. and L.A. performed operations and follow up. B.C. conceived the manuscript. G.B.L. wrote the manuscript.

EOC

:   epithelial ovarian cancer

BOT

:   border line ovarian tumor

OS

:   overall survival

P53

:   protein 53 EGFR, oncogenes epidermal growth factor receptor

HER-2/neu

:   human epidermal growth factor receptor 2

Bcl-2

:   B-cell lymphoma 2

RT

:   residual tumor

HR

:   hazard ratio

ICAM

:   soluble intercellular adhesion molecule

STROBE

:   Strengthening the Reporting of Observational Studies in Epidemiology

TEH

:   total extrafascial hysterectomy

BSO

:   bilateral salpingo- oophorectomy
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###### 

AB0 blood groups and epithelial ovarian cancers: results reported in literature.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Year                                                                                                                                                                                                                                                First Author (reference)   Ethnicity                                                 Sample Size                              Age (n)               Histology (n)                  Grading (n)   FIGO (n)    Lymphnode Stats(n)   Recurr.     OS           0 % (n)          P value    A % (n)       P value      B % (n)          P value   AB % (n)         P value    
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------- --------------------------------------------------------- ---------------------------------------- --------------------- ------------------------------ ------------- ----------- -------------------- ----------- ------------ ---------------- ---------- ------------- ------------ ---------------- --------- ---------------- ---------- --
  2018                                                                                                                                                                                                                                                Seebacher V.               Caucasian (Austria)                                       518                                      61.7                  High-grade serous (310)                                                                                41 (127)         0.4        40.3 (125)    0.4          12.6 (39)        0.4       6.1 (19)         0.4        

  Conclusions: ABO blood groups and RH factor are both neither associated with features of biologically aggressive disease nor clinical outcome in patients with EOC.                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  2018                                                                                                                                                                                                                                                Sartorius C.M.             Caucasian                                                 282                                      60.7 (sd+/-13.7)      Serous (160)                                                                                           56.4(53)                    65.9(83)                   64.5(20)                   40(4)                       

  Endometroid (42)                                                                                                                                                                                                                                                               17.0(16)                                                  14.3(18)                                 19.4(6)               20(2)                                                                                                                                                                                                                

  Mucinous (21)                                                                                                                                                                                                                                                                                                                            8.5(8)                                   6.3(8)                12.9(4)                        10(1)                                                                                                                                                                                 

  Clear cell (11)                                                                                                                                                                                                                                                                5.3(5)                                                    3.1(4)                                   0(0)                  20(2)                                                                                                                                                                                                                

  Neuroendocrine (1)                                                                                                                                                                                                                                                                                                                       1.0(6)                                   0(0)                  0(0)                           0(0)                                                                                                                                                                                  

  Mixed/ Unknown (26)                                                                                                                                                                                                                                                            11.7(11)                                                  10.3(13)                                 3.2(1)                10(1)                                                                                                                                                                                                                

                                                                                                                                                                                                                                                      G1(34)                                                                                                                                                                             17.5(14)                  13.7(14)                         19.2(5)                       12.5(1)                                                                                      

  G2(35)                                                                                                                                                                                                                                                                         21.2(17)                                                  11.8(12)                                 19.2(5)               12.5(1)                                                                                                                                                                                                              

  G3 (147)                                                                                                                                                                                                                                                                       61.3(49)                                                  74.5(76)                                 61.5(16)              75(6)                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                 I (64)                                                                                                                                                  23.9(22)                  23.7(27)                         35.5(11)                      40(4)                                                                                        

  II (21)                                                                                                                                                                                                                                                                        10.9(10)                                                  7.0(8)                                   6.4(2)                10(1)                                                                                                                                                                                                                

  III (126)                                                                                                                                                                                                                                                                      47.8(44)                                                  53.5(61)                                 54.8(17)              40(4)                                                                                                                                                                                                                

  IV (36)                                                                                                                                                                                                                                                                        17.4(16)                                                  15.8(18)                                 3.2(1)                10(1)                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        YES (108)                33.0(33)                    37.7(52)                   55.9(19)                   40(4)                       

  NO (174)                                                                                                                                                                                                                                            67.0(67)                   62.3(86)                                                  44.1(15)                                 60(6)                                                                                                                                                                                                                                      

  Conclusions: Relapse-free survival (RFS) in OC was significantly influenced the ABO blood groups. BG 0 and B were associated to an increased risk for recurrence compared to BG A (*p value*= 0.039). No difference in OS was found.                                                                                                                                                                                                                                                                                                                                                                                         

  2015                                                                                                                                                                                                                                                Zhou J.                    Asian (China)                                             256                                                                                                                                                                                                                                                                                 

  \< 50 (134)                                                                                                                                                                                                                                                                                                                                                                                                                                          50 (68)     \< 0.001             13.4(18)    \< 0.001     22.4 (30)        \< 0.001   13,4 (18)     *\< 0.001*                                                          

  \> 50 (122)                                                                                                                                                                                                                                                                                                                                                                                                                                          42.6 (52)   34.4(42)                         18(22)                        4.9(6)                                                                                       

                                                                                                                                                                                                                                                      Serous (208)                                                                                                                                                                                     47.1(98)    0.21                 25(52)      0.21         20.2(42)         0.21       7.7(16)       *0.21*                                                              

                                                                                                                                                                                                                                                      Non-serous (48)                                                                                                                                                                                  45.8(22)    16.7(8)                          20.8(10)                      16.7(8)                                                                                      

                                                                                                                                                                                                                                                                                 G1(28)                                                                                                                                                                28.6(8)     0.160                28.6(8)     0.160        0.36(10)         0.160      7.1(2)        *0.160*                                                             

                                                                                                                                                                                                                                                                                 G2 (126)                                                                                                                                                              46(58)                           27(34)                   17.5(22)                    9.5(12)                                                                           

                                                                                                                                                                                                                                                                                 G3 (102)                                                                                                                                                              52.9(54)                         17.6(18)                 19.6(20)                    9.8(10)                                                                           

                                                                                                                                                                                                                                                                                                                                           I (82)                                                                                                      44(36)      0.385                22(18)      0.385        22(18)           0.385      12.2(10)      *0.385*                                                             

                                                                                                                                                                                                                                                                                                                                           II (66)                                                                                                     39.4(26)                         24.2(16)                 24.2(16)                    12.1(8)                                                                           

                                                                                                                                                                                                                                                                                                                                           III (108)                                                                                                   53.7(58)                         24.1(26)                 16.7(18)                    5.5(6)                                                                            

                                                                                                                                                                                                                                                                                                                                                                                    Negative (172)                                                     45.3(78)    0.101                25.6(44)    0.101        17.4(30)         0.101      11.6(20)      *0.101*                                                             

                                                                                                                                                                                                                                                                                                                                                                                    Positive (84)                                                      50(42)                           19(16)                   26.2(22)                    4.8(4)                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                         5 years OS    70.00%      0.003                55%         0.003        83.3             0.003      82.5          *0.003*                                                             

  Conclusions: ABO blood type positively correlated only with age. About OS, patients with blood type A had a significantly worse OS than patients with non A blood type, especially in patients with age\> 50 yrs.                                                                                                                                                                                                                                                                                                                                                                                                            

  2014                                                                                                                                                                                                                                                Zhang B.                                                                             Meta-analysis 7 studies, 9956 patients                                                                                                                                                                                                                                              

  Conclusions: Blood group A was associated with increased risk of ovarian cancer and blood group 0 was associated with decreased risk.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  2012                                                                                                                                                                                                                                                Poole EM                   Caucasian                                                 8 studies, 5233 patients                                                                                                                                              42%              0.03       44            0.03         10%              0.03      4                *0.03*     

  Conclusions: The A blood group was associated with a modestly increased ovarian cancer risk. In diplotype analysis the A0, but not AA diplotype, was associated with increased risk. Neither AB nor the B blood groups were associated with risk.                                                                                                                                                                                                                                                                                                                                                                            

  2012                                                                                                                                                                                                                                                Yuzhalin AE                Caucasian (Siberia)                                       551                                      Premenopausal (225)                                                                                                          26,2(59)         \-         40.9(92)      0.0056       23.1(52)         0.0847    9.8(22)          *0.0756*   

  Postmenopausal (326)                                                                                                                                                                                                                                                           27.6(90)                                                  \-                                       34.7%(113)            0.0821                         27(88)        0.0041      10.7%(35)            *0.0151*                                                                                                                               

  Conclusions: A strongly correlated with an increased risk of ovarian cancer in premenopausal but not in postmenopausal woman. Conversly blood types B and AB were                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  2010                                                                                                                                                                                                                                                Gates MA                   Caucasian (US)                                            234                                                            All epithelian cancers (234)                                                                           41(96)           \-         31.2(73)                   17.5%(41)        \-        10.3(24)         *-*        

  Serous invasive (152)                                                                                                                                                                                                                                                          40.1(61)                                                  \-                                       30.3(46)                                             17.8(27)      \-          11.9(18)             *-*                                                                                                                                    

  Others(82)                                                                                                                                                                                                                                                                     \-                                                        \-                                       \-                                                   \-                        \-                                                                                                                                                          

  Conclusions: The B antigen was positively associated with ovarian cancer incidence, whereas blood group A was not associated with risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  1995                                                                                                                                                                                                                                                Marinaccio M.              Caucasian (Italy)                                                                                                                                                     I (28)                                       5 years OS   24.4(6)          0.0007     57.1(16)      0.0007       17.9(5)          0.0007    3.6(1)                      

  II (27)                                                                                                                                                                                                                                                                        5 years OS                                                48.1(13)                                 37(10)                14.8(4)                        \-                                                                                                                                                                                    

  Conclusions: Patients with blood type A had a significantly worse OS than non A ones                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  1993                                                                                                                                                                                                                                                Henderson J.               Caucasian (UK)                                            1261                                                           All ovarian cancer (1261)                                                                              41.1(518)                   46.1(587)                  9(114)                     3.3(42)          \          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \          

  Adenocarcinoma (1011)                                                                                                                                                                                                                                                          41.5(420)                                                 46(465)                                  9.2(93)                                              3.3(33)                                                                                                                                                                               

  Anaplastic tumor (73)                                                                                                                                                                                                                                                          43.8(32)                                                  45.2(33)                                 11(8)                                                0(0)                                                                                                                                                                                  

  Special ovarian tumors (47)                                                                                                                                                                                                                                                    44.7(21)                                                  42.5(20)                                 4.2(2)                                               8.5(4)                                                                                                                                                                                

  Other epitelian tumors (23)                                                                                                                                                                                                                                                    47.8(11)                                                  39.1(9)                                  4.3(1)                                               8.7(2)                                                                                                                                                                                

  Unspecified (107)                                                                                                                                                                                                                                                                                                                        31.8(34)                                                       56.1(60)                       9.3(10)                   2.8(3)                                                                                                                                                      

  Conclusions: Ovarian cancer was more common in women of blood group A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  1987                                                                                                                                                                                                                                                Marinaccio.                Caucasian (Italy)                                         189                                                                                                                                                                   31.0             \<0.001    52.0          \<0.001      13.3                       3.7                         

  Conclusions: Blood group A was associated with oc                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  1985                                                                                                                                                                                                                                                Illeni MT                  Caucasian (Italy)                                         65                                                                                                                                                                    29.23(19)        0.002      52.31(34)     0.002        13.85(9)         0.002     4.61(3)          *0.002*    

  Conclusions: OC patients present an increased and a decreased frequency of the A and 0 blood phenotypes.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  1984                                                                                                                                                                                                                                                Mori M.                    Asian (Japan)                                             80                                       48.6+/-12.8                                                                                                                  no significant              46.3          \<0.05       no significant             no significant              

  Conclusions: The proportion of ovarian cancer patients with blood group A was significantly high                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  1984                                                                                                                                                                                                                                                Bjorkholm E.               Caucasian (Sweden)                                        1930                                                                                                                                                                  52.4 (1011)                 10.5% (202)                4.4% (85)                  32.8% (632)                 

  Conclusions: High frequency of blood group A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  1967                                                                                                                                                                                                                                                Cozzi M. et al             Caucasian (Germany, Austria, Englang) and Asian (Japan)   1844                                                                                                                                                                  34.4(635)                   45.6(841)                  14.4(266)                  5.5(102)                    

  Conclusions: Blood group A was associated with increased risk of ovarian cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  1963                                                                                                                                                                                                                                                Osborne RH.                Caucasian (US)                                            713                                                                                                                                                                   39.97(285)       0.025      44.04(314)    0.025        11.50(82)        \-        4.49(32)                    

  Benign 260                                                                                                                                                                                                                                                                     37.79(98)                                                 0.07                                     43.85(114)            0.07                           13.46(35)     \-          5(13)                                                                                                                                                       

  Malignant 453                                                                                                                                                                                                                                                                  41.28(187)                                                0.10                                     44.15(200)            0.10                           10.38(47)     \-          4.19(19)                                                                                                                                                    

  Conclusions: In OC blood group A was associated with cancer risk but when benign and malignant disease are examined separately the results are not statistically significant                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  1959                                                                                                                                                                                                                                                Cutrera A                  Caucasian (Italy)                                         200                                                                                                                                                                   39(78)                      52%(104)                   9%(18)                     \-                          
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###### 

Analysis of association between blood groups and clinical and pathological characteristics of patients with BOT and EOC.

                                                  Blood Groups                                                                                  
  ---------------------------------- ------------ -------------- ---- ----------- ----------- ----------- -- ----------- ------- -- ----------- -------
                                     265          121                             112                        23                     9           
  **Age**                                                                                                                                       
  *≤61*                              133 (50.1)   59 (48.8)      \-               56 (50.0)   0.850          13 (56.5)   0.496      5 (55.6)    0.695
  *\>61*                             132 (49.9)   62 (51.2)           56 (50.0)               10 (43.5)      4 (44.4)                           
  **Ipertension**                                                                                                                               
  *No*                               143 (57.7)   63 (54.8)      \-               64 (60.4)   0.401          11 (55.0)   0.986      5 (71.4)    0398
  *Yes*                              105 (42.3)   52 (45.2)           42 (39.6)               9 (45.0)       2 (28.6)                           
  *NA*                               17           6                               6                          3                      2           
  **Diabetes**                                                                                                                                  
  *No*                               226 (93.0)   102 (91.9)     \-               99 (93.4)   0.672          18 (94.7)   0.670      7 (100.0)   0.992
  *Yes*                              17 (7.0)     9 (8.1)             7 (6.6)                 1 (5.3)        0 (0.0)                            
  *NA*                               22           10                              6                          4                      2           
  **FIGO_stage**                                                                                                                                
  *I-II*                             69 (30.3)    33 (32.3)      \-               27 (27.3)   0.405          7 (36.8)    0.723      2 (22.2)    0.523
  *III-IV*                           159 (69.7)   68 (67.3)           72 (72.7)               12 (63.2)      7 (77.8)                           
  *NA*                               37           20                              13                         4                      0           
  **Grade**                                                                                                                                     
  *G1*                               29 (12.9)    13 (13.3)      \-               13 (13.1)   0.978          2 (9.5)     0.641      1 (14.3)    0.939
  *G2*                               17 (7.5)     5 (5.1)             11 (11.1)               1 (4.8)        0 (0.0)                            
  *G3*                               179 (79.6)   80 (81.6)           75 (75.8)               18 (85.7)      6 (85.7)                           
  *NA*                               40           23                              13                         2                      2           
  **Postoperative residual tumor**                                                                                                              
  *No*                               183 (87.6)   83 (86.5)      \-               76 (87.4)   0.978          16 (88.9)   0.641      8 (100.0)   0.939
  *Yes*                              26 (12.4)    13 (13.5)           11 (12.6)               2 (11.1)       0 (0.0)                            
  *NA*                               56           25                              25                         5                      1           
  **Neoadjuvant treatment in EOC**   224          100                             95                         21                     8           
  *No*                               160 (76.2)   75 (78.1)      \-               65 (74.7)   0.587          14 (73.7)   0.673      6 (75.0)    0.838
  *Yes*                              50 (23.8)    21 (21.9)           22 (25.3)               5 (26.3)       2 (25.0)                           
  *NA*                               14           4                               8                          2                      0           
  **Invasiveness**                                                                                                                              
  *Borderline*                       40 (15.2)    20 (16.7)      \-               17 (15.2)   0.757          2 (8.7)     0.341      1 (11.1)    0.666
  *Invasive*                         224 (84.8)   100 (83.3)          95 (84.8)               21 (91.3)      8 (88.9)                           
  *NA*                               1            1                               0                          0                      0           
  **Histology**                                                                                                                                 
  *Serous*                           191 (72.3)   82 (68.3)      \-               83 (74.1)   0.333          19 (82.6)   0.177      7 (77.8)    0.558
  *Not serous*                       73 (27.7)    38 (31.7)           29 (25.9)               4 (17.4)       2 (22.2)                           
  *NA*                               1            1                               0                          0                      0           
  **Death**                                                                                                                                     
  *No*                               183 (69.1)   79 (65.3)      \-               76 (67.9)   0.678          21 (91.3)   0.024      7 (77.8)    0.451
  *Yes*                              82 (30.9)    42 (34.7)           36 (32.1)               2 (8.7)        2 (22.2)                           
  **Recurrence**                                                                                                                                
  *No*                               117 (57.6)   56 (57.1)      \-               52 (60.5)   0.749          6 (42.9)    0.304      3 (60.0)    0.663
  *Yes*                              86 (42.2)    42 (42.9)           34 (39.5)               8 (57.1)       2 (40.0)                           
  *Persistence of disease*           26           13                              11                         2                      0           
  *NA*                               36           10                              15                         7                      4           

###### 

Overall survival analysis in BOT and EOC patients with different AB0 groups.

                                         Patients (n)   Events (n,%)   Median (months)   HR     Pvalue
  -------------------------------------- -------------- -------------- ----------------- ------ --------
  **Total population (BOT+EOC) (265)**                                                          
  0                                      121            42 (34.7)      61                       
  A                                      112            36 (32.1)      71                0.88   0.588
  B                                      23             2 (8.7)        NA                0.16   0.011
  AB                                     9              2 (22.2)       NA                0.66   0.572
  **EOC (224)**                                                                                 
  0                                      100            39 (39.0)      57                       
  A                                      95             32 (33.7)      71                0.83   0.433
  B                                      21             2 (9.5)        NA                0.18   0.018
  AB                                     8              2 (25.0)       NA                0.74   0.677
  **Serous EOC (176)**                                                                          
  0                                      75             31 (41.3)      51                       
  A                                      77             26 (33.8)      56                0.85   0.538
  B                                      18             2 (11.1)       NA                0.20   0.027
  AB                                     6              2 (33.3)       49                0.87   0.847

The analysis was performed on total study population (BOT+EOC) and on patients with only EOC and only serous EOC.

###### 

Univariate and multivariate analysis of survival in serous EOC. In multivariate analysis model 1 neoadjuvant therapy and presence of postoperative residual tumor were excluded, while they were considered in model 2.

                                 Univariate Cox Model   Multivariate Cox Model 1   Multivariate Cox Model 2                              
  ------------------------------ ---------------------- -------------------------- -------------------------- ------- ------------------ --------
  **AB0 group**                                                                                                                          
  *0*                            1                      \-                         1                          \-                         
  *A*                            0.85 (0.50-1.43)       0.537                      0.82 (0.44-1.55)           0.544   0.81 (0.37-1.75)   0.587
  *B*                            0.20 (0.05-0.83)       0.027                      0.20 (0.04-0.93)           0.041   0.32 (0.07-1.51)   0.149
  *AB*                           0.87 (0.21-3.65)       0.847                      1.59 (0.36-7.02)           0.539   3.55 (0.71-17.8)   0.123
  Age                            1.03 (1.00-1.05)       0.016                      1.04 (1.01-1.07)           0.015   1.07 (1.03-1.11)   0.0003
  Ipertension                    1.23 (0.73-2.09)       0.438                      1.07 (0.53-2.16)           0.847   1.65 (0.75-3.64)   0.212
  Diabetes                       1.31 (0.47-3.64)       0.606                      1.20 (0.26-5.52)           0.814   1.21 (0.24-6.00)   0.820
  **FIGO stage**                                                                                                                         
  *I-II*                         1                      \-                         1                          \-      \-                 \-
  *III-IV*                       2.19 (0.68-7.02)       0.188                      1.63 (0.50-5.33)           0.418   1.50 (0.19-11.9)   0.702
  **Grade**                                                                                                                              
  *G1-G2*                        1                      \-                         1                          \-      1                  \-
  *G3*                           3.73 (0.52-27.0)       0.193                      2.33 (0.31-17.26)          0.409   1.72 (0.22-13.4)   0.608
  Postoperative residual tumor   2.28 (1.14-4.57)       0.020                      \-                         \-      3.98 (1.63-9.71)   0.002
  Neoadjuvant treatment          1.76 (0.94-3.28)       0.078                      \-                         \-      1.42 (0.63-3.24)   0.401
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